Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Carbonic anhydrases (CA) influence intra- and extracellular pH and ion transport in varied biological processes. We recently identified CA9 and CA12 as hypoxia-inducible genes. In this study we examined the expression of these tumor-associated CAs by immunohistochemistry in relation to necrosis and early breast tumor progression in 68 cases of ductal carcinoma in situ (DCIS) (39 pure DCIS and 29 DCIS associated with invasive carcinoma). CA IX expression was rare in normal epithelium and benign lesions, but was present focally in DCIS (50% of cases) and in associated invasive carcinomas (29%). In comparison, CA XII was frequently expressed in normal breast tissues (89%), in DCIS (84%), and in invasive breast lesions (71%). In DCIS, CA IX was associated with necrosis (P: = 0.0053) and high grade (P: = 0.012). In contrast, CA XII was associated with the absence of necrosis (P: = 0.036) and low grade (P: = 0.012). Despite this, augmented CA XII expression was occasionally observed adjacent to necrosis within high-grade lesions. Neither CA IX nor CA XII expression was associated with regional or overall proliferation as determined by MIB1 staining. Assessment of mammographic calcification showed that CA XII expression was associated with the absence of calcification (n = 43, P: = 0.0083). Our results demonstrate that induction of CA IX and CA XII occurs in regions adjacent to necrosis in DCIS. Furthermore, these data suggest that proliferation status does not influence expression of either CA in breast tissues, that hypoxia may be a dominant factor in the regulation of CA IX, and that factors related to differentiation, as determined by tumor grade, dominate the regulation of CA XII. The existence of differential regulation and associations with an aggressive phenotype may be important in the development of selective inhibitors of CAs, because the latter have recently been shown to prevent tumor invasion.
Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom.
C C
CC
Wykoff
N
N
Beasley
P H
PH
Watson
L
L
Campo
S K
SK
Chia
R
R
English
J
J
Pastorek
W S
WS
Sly
P
P
Ratcliffe
A L
AL
Harris
D000918:Antibody Specificity; D034961:Antigens, Nuclear; D015415:Biomarkers / Q000032:analysis; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001940:Breast / Q000201:enzymology; D001943:Breast Neoplasms / Q000201:enzymology* / Q000473:pathology; D002114:Calcinosis / Q000201:enzymology / Q000473:pathology; D002256:Carbonic Anhydrases / Q000276:immunology / Q000378:metabolism*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000201:enzymology* / Q000473:pathology; D002455:Cell Division; D015687:Cell Hypoxia; D005260:Female; D015870:Gene Expression; D006801:Humans; D009336:Necrosis; D009687:Nuclear Proteins / Q000032:analysis; D020033:Protein Isoforms / Q000276:immunology / Q000378:metabolism; D014407:Tumor Cells, Cultured
D034961:Antigens, Nuclear; D015415:Biomarkers; D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; D020033:Protein Isoforms; D002256:Carbonic Anhydrases